Alzheimer’s disease research saw notable progress with new clinical data supporting amyloid-clearing therapies like Eisai and Biogen's Leqembi, including promising autoinjector formulations that could enhance patient access and compliance. Additional studies highlighted a cardiovascular drug’s potential to lower AD biomarkers such as p-tau217, suggesting novel preventative strategies. Concurrently, AI-driven pathological assessment tools are advancing lung adenocarcinoma grading, paving the way for improved diagnostic accuracy and prognosis prediction in neurodegenerative and oncologic disorders.